| Plasma AR and abiraterone-resistant prostate cancer A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... Science translational medicine 7 (312), 312re10-312re10, 2015 | 461 | 2015 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 275 | 2017 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 206 | 2015 |
| ETS fusion genes in prostate cancer DG Tandefelt, J Boormans, K Hermans, J Trapman Endocrine-related cancer 21 (3), R143-R152, 2014 | 104 | 2014 |
| Overexpression of prostate-specific TMPRSS2 (exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer KG Hermans, JL Boormans, D Gasi, GJHL van Leenders, G Jenster, ... Clinical Cancer Research 15 (20), 6398-6403, 2009 | 104 | 2009 |
| A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers DG Tandefelt, JL Boormans, HA van der Korput, GW Jenster, J Trapman European urology 64 (6), 941-950, 2013 | 42 | 2013 |
| Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer V Conteduca, D Wetterskog, E Scarpi, A Romanel, G Gurioli, A Jayaram, ... British journal of cancer 123 (6), 982-987, 2020 | 29 | 2020 |
| Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation D Gasi, HA van der Korput, HC Douben, A de Klein, CM de Ridder, ... PloS one 6 (1), e16332, 2011 | 29 | 2011 |
| Identification of single nucleotide variants using position-specific error estimation in deep sequencing data D Kleftogiannis, M Punta, A Jayaram, S Sandhu, SQ Wong, ... BMC Medical Genomics 12, 1-12, 2019 | 9 | 2019 |
| Androgen regulation of ETS gene fusion transcripts in prostate cancer D Gasi, J Trapman Androgen Action: Methods and Protocols, 335-348, 2011 | 9 | 2011 |
| Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Ann Oncol 28 (7), 1508-1516, 2017 | 8 | 2017 |
| The key role of patient involvement in the development of core outcome sets in prostate cancer K Beyer, SJ MacLennan, L Moris, M Lardas, K Mastris, G Hooker, ... European Urology Focus 7 (5), 943-946, 2021 | 7 | 2021 |
| Circulating cell-free DNA: Translating prostate cancer genomics into clinical care DG Tandefelt, J de Bono Molecular Aspects of Medicine 72, 100837, 2020 | 7 | 2020 |
| Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 7: 312re10 A Romanel, D Gasi Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... | 7 | 2015 |
| Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015; 7: 312re10 A Romanel, D Gasi Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... | 7 | |
| Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG … N Sampson, P Berger, H Klocker European urology 65 (6), e102-e103, 2014 | 4 | 2014 |
| Expression and function of ETS genes in prostate cancer DG Tandefelt PhD dissertation, Dept. Pathology, Erasmus MC, Erasmus Univ. Rotterdam …, 2013 | 2 | 2013 |
| Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015; 7 (312): 312 A Romanel, D Gasi Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... | 2 | |
| Survivorship data in Prostate Cancer: Where are we and where do we need to be? B Russell, K Beyer, A Lawlor, MJ Roobol, LDF Venderbos, S Remmers, ... European Urology Open Science 59, 27-29, 2024 | 1 | 2024 |
| Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC). V Conteduca, D Wetterskog, MTA Sharabiani, A Jayaram, S Salvi, ... Journal of Clinical Oncology 35 (15_suppl), 5060-5060, 2017 | | 2017 |
Gerhardt AttardUniversity College London Cancer Institute在 ucl.ac.uk 的电子邮件经过验证
